- Semaglutide targets GLP-1R, tirzepatide combines GIPR and GLP-1R activity, and retatrutide is designed for GIPR, GLP-1R and GCGR agonism.
- These are sequence- and modification-specific molecules; names alone are insufficient for procurement.
- Lipidation and closely related impurities make LC-MS method design important.
- Retatrutide remains investigational and is not FDA-approved as of August 2026. This article is not clinical guidance.
The short answer: single, dual and triple receptor design
Semaglutide is a modified GLP-1 analogue designed around GLP-1 receptor activity. Tirzepatide is a single peptide with activity at GIP and GLP-1 receptors. Retatrutide is an investigational peptide designed to activate GIP, GLP-1 and glucagon receptors. Structural research shows distinct receptor interactions for retatrutide compared with semaglutide and tirzepatide [1].
This receptor description is a molecular classification, not an instruction for use or a claim that research materials are interchangeable with approved medicines. FDA has specifically warned about unapproved GLP-1 products falsely presented as research material, and states that retatrutide is not a component of an FDA-approved drug [2].
Why sequence and lipidation matter
All three molecules use engineered sequences and long-chain acyl modifications to change receptor pharmacology and molecular behavior. The position and chemistry of the lipid side chain, linker architecture and non-canonical residues are part of the identity. A generic label such as 'GLP-1 peptide' cannot establish sameness.
For technical purchasing, specify the exact molecule, sequence reference, molecular formula or mass, modification site, counter-ion, purity, content basis and analytical package. The vial fill alone does not define the material.
Analytical comparison for research procurement
Acylated peptides can present chromatographic and mass-spectrometric challenges. Related impurities may include deletion sequences, incomplete modification, oxidation, deamidation, epimers and aggregates. HPLC purity should therefore be interpreted with the method, while high-resolution MS or LC-MS supports molecular identity and impurity assignment.
A buyer should request lot-specific HPLC and MS, peptide content or another defined quantity basis, water and counter-ion information where relevant, and storage instructions. Closely related peaks or unexpected mass differences require technical investigation rather than acceptance based on a headline percentage.
Current regulatory context matters
Semaglutide and tirzepatide are active ingredients in FDA-approved medicines for specific indications and presentations. That approval does not extend to unapproved bulk, compounded or research-labeled products. Retatrutide remains investigational; Lilly reported Phase 3 topline results in 2026 and states that regulatory submission is planned, but it is not currently approved [3].
PeptideSum catalog materials are offered for qualified research or other expressly stated non-human-use contexts. They are not medicines, compounded drug ingredients or substitutes for licensed products. The site does not provide dosing, administration or personal-use advice.
How to compare supplier offers responsibly
Compare offers on exact identity, lot documentation, analytical method, purity, content, packaging, storage, shipping and legal end-use—not price per nominal milligram alone. Confirm whether the quoted amount is peptide content or gross lyophilized mass and whether the COA belongs to the supplied lot.
For laboratory programs, define the assay and acceptance criteria before ordering. PeptideSum's product catalog, COA review and technical inquiry routes are designed to connect the named material with its specification and documentation.
This article is for laboratory, analytical, procurement and qualified cosmetic-science contexts. It is not medical advice and does not provide dosing, administration or personal-use instructions.
Frequently asked questions
What is the main difference between semaglutide, tirzepatide and retatrutide?+
At a high level, semaglutide is GLP-1 receptor focused, tirzepatide is a GIP/GLP-1 dual agonist, and retatrutide is designed as a GIP/GLP-1/glucagon triple agonist.
Is retatrutide FDA-approved in 2026?+
No. As of August 2026, retatrutide remains investigational and is not approved by FDA or another regulatory agency, according to its developer.
Can these research peptides be compared by HPLC purity alone?+
No. Exact sequence, modification, molecular identity, peptide content, impurity profile, counter-ion and method conditions also matter.
Are research materials equivalent to approved GLP-1 medicines?+
No. Research materials are not approved medicines and must not be represented or used as substitutes for licensed drug products.